Through Phase 1 clinical trials, it has been confirmed that there is no drug interaction when Dapagliflozin and Olmesartan are co-administered, and PK (Pharmacokinetic) equivalence has been established between the co-administration and combination therapy groups. Currently, Phase 3 clinical trials are ongoing at institutions such as Bundang Seoul National University Hospital, etc.

Overview of Clinical Trials

• Title: A Randomized, Active-controlled, Double-blind, Parallel, Multi center, Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated Olmesartan and Dapagliflozin in Patients with Essential Hypertension and Type II Diabetes Mellitus
• Subjects: 248 patients with Essential Hypertension and Type II Diabetes

Primary Endpoints

• Change of MSSBP from baseline
• Change of HbA1c from baseline